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Factors predictive of skeletal-related events (SREs) in bone metastatic prostate cancer patients with hormone-refractory disease were
investigated. We evaluated the frequency of SREs in 200 hormone-refractory patients consecutively observed at our Institution and
followed until death or the last follow-up. Baseline parameters were evaluated in univariate and multivariate analysis as potential
predictive factors of SREs. Skeletal-related events were observed in 86 patients (43.0%), 10 of which (5.0%) occurred before the
onset of hormone-refractory disease. In univariate analysis, patient performance status (P¼0.002), disease extent (DE) in bone
(P¼0.0001), bone pain (P¼0.0001), serum alkaline phosphatase (P¼0.0001) and urinary N-telopeptide of type one collagen
(P¼0.0001) directly correlated with a greater risk to develop SREs, whereas Gleason score at diagnosis, serum PSA, Hb, serum
albumin, serum calcium, types of bone lesions and duration of androgen deprivation therapy did not. Both DE in bone (hazard ratio
(HR): 1.16, 95% confidence interval (CI): 1.07–1.25, P¼0.000) and pain score (HR: 1.13, 95% CI: 1.06–1.20, P¼0.000) were
independent variables predicting for the onset of SREs in multivariate analysis. In patients with heavy tumour load in bone and great
bone pain, the percentage of SREs was almost twice as high as (26 vs 52%, Po0.02) and occurred significantly earlier (P¼0.000) than
SREs in patients with limited DE in bone and low pain. Bone pain and DE in bone independently predict the occurrence of SREs in
bone metastatic prostate cancer patients with hormone-refractory disease. These findings could help physicians in tailoring the
skeletal follow-up most appropriate to individual patients and may prove useful for stratifying patients enrolled in bisphosphonate
clinical trials.
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Prostate cancer is the most commonly diagnosed malignancy
among elderly men and the second most common cause of cancer-
related death in men in Italy and other European countries (De
Angelis et al, 1997). In patients with prostate cancer, bone is by far
the most common site of distant metastases. More than 80% of
men with advanced disease will, in fact, eventually develop skeletal
involvement. Bone metastases are devastating events in the natural
history of the disease since they are often painful and cause skeletal
complications such as pathologic fracture, vertebral collapse and
spinal cord compression (Berruti et al, 2000; Bayley et al, 2001;
Mundy, 2002). Androgen suppression by either orchiectomy or
administration of luteinising hormone-releasing hormone analogs
(LHRH-A) is the mainstay of treatment for advanced prostate
cancer patients. This therapy frequently produces tumour shrink-
age and improvement in symptoms, but it is not curative since
almost all patients will eventually develop hormone-refractory
disease. Once the disease becomes refractory to hormonal
manipulation, the prognosis is dismal and the overall survival is
about 13–16 months (Smaletz et al, 2002; Halabi et al, 2003).
We have previously observed that skeletal-related events (SREs)
in prostate cancer patients are relatively rare as long as the disease
is responsive to hormones, but they occur much more often when
the tumour becomes hormone refractory (Berruti et al, 2000).
Zoledronic acid, a potent bisphosphonate, significantly reduces the
onset of skeletal complications in this patient population (Saad
et al, 2002). Recent reports point out, however, that administration
of this drug is not cost-effective (Reed et al, 2004). Other available
treatment options include intensive supportive care, radiotherapy,
second-line hormonal manipulations, cytotoxic chemotherapy and
investigational agents (Goodin et al, 2002). In two recent
randomised independent clinical trials, chemotherapy reportedly
improved response rate and survival (Petrylak et al, 2004; Tannock
et al, 2004). However, because the survival benefit is modest,
treatment options for bone metastatic patients with hormone-
refractory disease are mainly palliative.
Since skeletal complications are the major causes of diminished
quality of life in this patient population (Groot et al, 2003), the
identification of baseline factors predictive for these adverse events
may be a valuable aid in tailoring to each patient the most
appropriate preventive measures and in potentially avoiding
unnecessary and costly treatments.
In advanced prostate cancer, the basic factors contributing to
skeletal-related morbidity may be broken down loosely into those Received 24 May 2005; revised 14 July 2005; accepted 2 August 2005
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srelated directly to the metastases and those of iatrogenic nature.
Androgen deprivation therapy causes osteoporosis and adverse
skeletal events independently of disease response and in the
absence of skeletal involvement (Daniell et al, 2000; Smith, 2003).
The frequency of adverse skeletal events induced by androgen
deprivation therapy depends mainly on the duration of therapy.
Long-lasting androgen deprivation therapy makes the skeleton
more fragile and may contribute to skeletal morbidity even in the
hormone-refractory phase of the disease.
In this study, the frequency of SREs was evaluated in a series of
hormone-refractory prostate cancer patients with metastatic bone
disease prospectively treated and followed at the Prostate Cancer
Unit of the Azienda Ospedaliera San Luigi di Orbassano, Italy. In
a previous publication on the first 112 cases (Berruti et al, 2000),
we identified several predictive factors, including serum alkaline
phosphatase (ALP), urinary deoxy-pyridinoline and disease extent
(DE) in bone. Here, we tested by univariate and multivariate
analyses a number of additional predictive factors for SREs,
including validated prognostic parameters, urinary N-telopeptide
of type one collagen (NTx) and duration of androgen deprivation
therapy.
PATIENTS AND METHODS
Patients
Eligible patients were required to have histologically proven
adenocarcinoma of the prostate with metastatic bone disease that
progressed to LHRH-A administration with or without antiandro-
gens. Disease progression was defined as a rise in prostate-specific
antigen (PSA) levels (X50% over the nadir obtained during
androgen deprivation) on two consecutive measurements per-
formed at least 2 weeks apart or a new lesion on bone scan and/
or an increase in the size of a measurable lesion on a computed
tomographic (CT) scan of the abdomen/pelvis or chest. The time
from diagnosis of hormone refractoriness to enrolment in the
study should have been not greater than 2 months.
Patients previously treated with LHRH-A alone underwent total
androgen ablation (obtained by adding an antiandrogen: flutamide
or bicalutamide). They entered the study if they showed further
evidence of disease progression after at least 4 weeks of combined
therapy. Patients previously treated with total androgen ablation
were required to undergo antiandrogen withdrawal. They were
required to be off all antiandrogens for at least 4 weeks, with
further evidence of disease progression after cessation of
antiandrogen treatment. Serum testosterone was routinely mea-
sured in all patients showing PSA progression under LHRH-A
since 1997. From this date onwards, testosterone inhibition
(defined as serum levels o50ngdl
 1) was added to the criteria
for hormone refractoriness. Further inclusion criteria comprised
an Eastern Cooperative Oncology Group (ECOG) performance
status (PS) of 0–3 and normal renal and hepatic function. Patients
were excluded from the study if they had severe uncontrolled
comorbidity, second malignancies, pretreatment with bisphos-
phonates, radiotherapy or radionuclide therapy for palliation of
bone pain, and second-line antineoplastic treatment. At study
entry, all patients underwent physical examination, including bone
pain assessment and neurological examination, routine blood
chemistry studies, serum PSA, serum ALP, bone scan followed by
radiological confirmation of hot spots, chest X-ray and whole
abdomen CT. Urinary NTx was measured in the last 103 patients.
When scintigraphy was positive and X-ray films were negative for
bone lesions, a CT study was performed. The whole skeleton was
arbitrarily divided into the following areas: skull, cervical, dorsal,
lumbar spineþsacrum, right leg, left leg, right arm, left arm, right
ribs, left ribs, sternum, right scapula and clavicula, left scapula and
clavicula, right pelvis and left pelvis. Disease extent in bone was
calculated as the sum of involved areas. In order to limit the
distribution of this variable, patients with X9 segments were
scored as 9. Baseline bone pain was evaluated using a validated
pain questionnaire, as previously reported (Berruti et al, 2002).
Questionnaire items included performance status, analgesic
consumption and mobility, as measured on a pain score of 0–
19. All patients subsequently received second-line treatment
consisting of endocrine therapy, chemotherapy, radiotherapy and
radionuclide therapy, as indicated in association with the best
palliative care. Physical and bone pain reassessment, routine blood
chemistry studies, bone markers and serum PSA were repeated at
least every 3 months. On detection of increased PSA, worsening
bone pain and/or impaired mobility, patients underwent bone
scanning followed by radiological confirmation of hot spots. When
pathological or impending fracture was diagnosed, patients were
referred to an orthopaedic surgeon. When deformity of 1 or more
vertebral bodies was detected or clinical evidence of spinal cord
compression was suspected, whole spine magnetic resonance
imaging (MRI) was performed to direct decision-making whether
to perform surgery or radiotherapy and/or prescribe spinal
orthosis. The study was approved by the Institutional Review
Board of our hospital. All patients were required to give written
informed consent before registration.
Study end points
Skeletal-related events were defined as vertebral body collapse
requiring spinal orthosis, spinal cord compression, vertebral and
nonvertebral pathological fractures, symptomatic hypercalcemia,
symptomatic hypocalcemia. Skeletal-related events also included
surgery and/or radiotherapy delivered to bone to stabilise or
prevent pathologic fractures or areas of spinal cord compression.
Neither radiation therapy nor radionuclide therapy for pain relief
nor change in antineoplastic therapy to treat bone pain were
considered SREs. Survival duration was defined as the time
between the diagnosis of hormone-refractory disease and death.
The date of hormone refractoriness was defined as the date of the
first rise in PSA or, in the rare cases of no PSA elevation, the date
of diagnosis of disease progression in skeletal or extraskeletal sites.
Patients were censored if they were known to be alive or were lost
to follow-up. The time to the onset of skeletal complications was
calculated as the time between the diagnosis of hormone-refractory
disease and the occurrence of the first SRE or death, whichever
event occurred first. Patients were censored if they were alive and
free of SREs. If the first SRE occurred before the onset of hormone
refractoriness, it was not computed in the analysis.
Biochemical measurements
Early morning spot urine specimens were obtained to measure
creatinine and N-telopeptide; blood samples were drawn to assess
calcium, albumin (ALB), PSA, total ALP, lactate dehydrogenasis
(LDH) and haemoglobin (Hb). N-telopeptide of type one collagen
was measured using a commercial kit (Osteomark, Ortho-Clinical
Diagnostics, Rochester, NY, USA), blood biochemical parameters
were measured using automated procedures (Architect, Abbott).
Statistical analysis
Differences in proportion were determined using the w
2 test.
Correlations between continuous variables were performed using
the nonparametric Spearman test. Survival curves were estimated
using the Kaplan–Meier method. Unadjusted differences in these
estimates were tested using the log-rank test. A univariate Cox
proportional hazards model was used to identify all statistically
significant predictors of SREs and death. A multivariate Cox
proportional hazards model was used to identify independent
variables predictive of the onset of SREs. Only those variables
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sfound to be significant on univariate analysis were included in a
multivariate proportional hazards model. Among these, serum
ALP and urinary NTx had right skewed distributions and were
modelled using log transformation. Two analyses were performed,
one on overall cases without including NTx and another on the 103
patients having NTx measured. The latter analysis should be
considered as explorative. All reported P-values were two-sided; P-
values o0.05 were considered statistically significant. Statistical
computation was performed using the SPSS for Windows software
package.
RESULTS
Patients
From July 1990 to January 2003, 200 consecutive patients with
newly diagnosed hormone-refractory prostate cancer meeting the
eligibility criteria were enrolled in the present study. Patient
characteristics are depicted in Table 1. Urinary NTx was available
for the last 103 patients, while in the first patients bone resorption
was measured by urinary deoxypyridinoline. Treatment for
hormone-refractory disease was chemotherapy in 74 patients
(estramustine alone, etoposideþestramustine, epirubicin, doce-
taxel) and steroids plus supportive care in the remaining 126 cases.
Previous LHRH-A administration was not interrupted in any cases.
Bone pain was present in 177 patients (88.5%); 72 (36.0%)
necessitated radiotherapy and or radionuclide therapy to control
pain symptoms; 32 (16.0%) also received single-dose pamidronate,
as previously reported (Berruti et al, 2002). As expected, a
significant correlation was found between DE in bone and either
ALP serum levels (Spearman R 0.51, Po0.01) or NTx urinary
values (Spearman R 0.40, Po0.01).
A total of 86 patients (43.0%) experienced skeletal complica-
tions, including vertebral collapse in 41 (20.5%), fractures in 25
(12.5%) and spinal cord compression in 20 (10.0%). Skeletal
fractures involved the vertebrae (seven patients), the ribs (six
patients), the femur (six patients), the scapula (one patient), the
pelvis (three patients), the humerus (one patient), the vertebrae
and ribs (one patient). Two patients developed symptomatic
hypercalcemia and one patient symptomatic hypocalcemia. Both
metabolic adverse events occurred concomitantly with other SREs
and were not computed separately.
All patients who experienced SREs received radiation therapy;
13 required surgery to bone. Additional SREs occurring in patients
who had already experienced an adverse skeletal event were not
considered in the analysis. In 10 (5.0%), the first adverse SRE
preceded the onset of hormone refractory disease; in 76 (38.0%) it
occurred afterwards. In those cases where SREs occurred before
hormone refractoriness, the median duration of androgen
deprivation therapy was 59.9 months (range 19.3–228.0) and
24.9 months in those where it did not (range 3.0–212.0, P¼0.004).
In the patients who experienced SREs in the hormone-refractory
phase of the disease, the median time to the onset of adverse events
was 7 months (range 1–39). At the last follow-up on 15 August
2004, 180 patients (90.0%) had died (median survival 14.5
months); 102 of which (56.7%) without experiencing SREs. Out
of 20 patients, 12 still alive were SRE-free, five of which were alive
more than 4 years since the date of the onset of hormone-
refractory disease.
Skeletal-related events according to baseline
characteristics
The proportion of patients with at least one SRE according to
baseline parameters and the univariate relative risks for the onset
of SREs and death is shown in Table 2. Skeletal-related events
occurring before the onset of hormone-refractory disease were not
considered in the analysis. Disease extent in bone, bone pain,
serum ALP and urinary NTx directly correlated with a higher risk
of developing adverse skeletal events over time (either in terms of
proportion of SREs or in terms of relative risk). Analysis of
Gleason score, serum PSA, Hb, serum albumin, serum calcium,
types of bone lesions and duration of androgen deprivation
therapy did not show any significant relationship between these
parameters and the occurrence of SREs. Performance status failed
to be significantly correlated with the frequency of SREs, while it
was significantly related with a higher risk of experiencing an SRE
over time.
Those variables attaining statistical significance in the univariate
analysis were included in the multivariate analysis. In the first
multivariate analysis of all cases, both DE in bone and bone pain
were independent variables predicting for SREs, while ALP and
patient performance status did not enter the model (Table 3). In
the multivariate analysis on patients with NTx assessed alone, DE
in bone and bone pain maintained an independent predictive role,
while NTx failed to enter the model (HR: 1.13, 95% CI: 0.71–1.77).
Disease extent in bone and bone pain (both considered
dichotomous variables as outlined in Table 1) were combined to
generate three patient subgroups: patients with DE in p6 sites and
a pain score of o5 (DE /Pain ), patients with DE in 46 sites and
a pain score of X5 (Painþ/DEþ) and patients with either of
these predictors (DE /Painþ or DEþ/Pain ). The distribution
of SREs in patients with Painþ/DEþ was double that of patients
with Pain /DE  (26.2 vs 52.5%, respectively, P¼0.016), while the
SRE frequency in patients with either of these two predictors was
intermediate (36.0%). Analysis of the time to onset of first SRE also
showed a time-dependent pattern (Figure 1). Patients with heavy
tumour load in bone and great bone pain (Painþ/DEþ)
developed SREs significantly earlier than those with limited DE
in bone and low pain (Pain /DE ) (RR: 1.63, 95% CI: 1.32–2.00).
Again, patients with either predictor showed an intermediate
pattern.
Table 1 Patient characteristics
No 200
Age median (year) (range) 73 (52–92)
ECOG PS
0 42 (21.0%
1 91 (45.5%)
2–3 67 (33.5%)
Gleason score at diagnosis (196 patients)
o8 95 (48.5%)
X8 101 (51.5%)
Previous endocrine therapies
LHRH-A 182 (91.0%)
LHRH-A+antiandrogens 18 (9.0%)
PSA (ngml
 1) (198 patients)
a 118.0 (0.1–9000.0)
Alkaline phosphatase (Ul
 1) (186 patients)
a 165.0 (47.0–6000.0)
NTx (nmolmmol
 1 creatinine) (103 patients)
a 96.0 (11.6–662.0)
Ca (mmoll
 1) (184 patients)
a 2.35 (1.91–4.20)
Hb (gdl
 1) (182 patients)
a 12.1 (7.3–15.6)
Albumin (gdl
 1) (170 patients)
a 3.6 (1.9–6.7)
LDH (Ul
 1) (178 patients)
a 405 (136–3011)
Androgen deprivation duration (months) (188 patients)
a 24.5 (2.03–228.0)
Disease extent in bone (number of sites) (198 patients)
a 6 (1–9 or more)
Pain score (200 patients)
a 5 (0–16)
Types of bone lesions (190 patients)
Lytic 14 (7.4%)
Mixed 42 (22.1%)
Blastic 134 (70.5%)
aData are median (range).
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sAll validated prognostic parameters such as Gleason score,
serum albumin, serum ALP, LDH, Hb and PSA were significantly
related with poor survival; in addition, DE in bone also showed a
negative relationship (Table 2).
DISCUSSION
Adverse skeletal events often lead to a deterioration in the quality
of life of prostate cancer patients (Weinfurt et al, 2005). In our
series of prospectively followed bone metastatic patients with
hormone-refractory disease, 43% experienced SREs, with 5%
occurring before and 38% after the onset of hormone-refractory
disease. The time to onset of the first adverse event in the
Table 2 Proportion of adverse skeletal related events (SREs), relative risks (RRs) and 95% confidence intervals (CIs) associated with SREs or death
Time to first SRE Time to death
Proportion SREs P-value RRs 95% CI P-value RRs 95% CI P-value
Performance status
0–1 47/135 (34.8%) 0.18 2.07 1.3–3.28 0.002 1.65 1.20–2.70 0.002
41 29/65 (44.6%)
Gleason score
o8 38/95 (40.0%) 0.59 1.03 0.60–1.80 0.90 1.31 1.07–1.62 0.01
X8 38/101 (37.6%)
PSA (ngml
 1)
p118 37/100 (37.0%) 0.79 1.37 0.87–2.15 0.18 1.42 1.05–1.93 0.02
4118 38/98 (38.7%)
Hb (gdl
 1)
p12.5 38/89 (42.7%) 0.66 0.89 0.56–1.42 0.63 0.61 0.43–0.88 0.003
412.5 38/93 (40.8%)
Albumin (gdl
 1)
p3.6 34/90 (37.7%) 0.66 0.85 0.53–1.36 0.49 0.64 0.46–0.88 0.007
43.6 34/83 (40.9%)
LDH (Ul
 1)
p405 32/75 (42.6%) 0.62 1.21 0.73–2.01 0.46 1.61 1.13–2.28 0.008
4405 29/75 (38.6%)
Types of bone lesions
Lytic/mixed 25/56 (44.6%) 0.28 0.85 0.53–1.36 0.50 1.00 0.72–1.41 0.97
Blastic 51/134 (38.1%)
Disease extent in bone
p6 sites 28/94 (29.8%) 0.015 2.41 1.50–3.88 0.0001 1.47 1.08–2.01 0.014
46 sites 48/103 (46.6%)
Bone pain
Pain score o5 31/105 (29.5%) 0.011 1.94 1.44–2.63 0.0001 1.53 1.27–1.85 0.0001
Pain score X5 44/95 (45.8%)
ALP (Ul
 1)
p165 29/94 (30.8%) 0.014 2.50 1.56–4.02 0.0001 1.71 1.25–2.35 0.001
4165 45/93 (48.4%)
NTx (nmolmmol
 1 creatinine)
p96 10/50 (20.0%) 0.001 3.10 1.47–6.54 0.001 1.37 0.90–2.06 0.14
496 31/53 (58.5%)
Ca (mmoll
 1)
p2.35 38/92 (41.3%) 0.65 0.64 0.35–1.17 0.15 1.10 0.80–1.51 0.54
42.35 35/92 (38.0%)
Duration of androgen deprivation therapy (months)
p24.4 41/94 (43.6%) 0.37 0.65 0.41–1.02 0.06 0.74 0.54–1.01 0.05
424.4 35/94 (37.2%)
Table 3 Independent factors predictive for adverse skeletal events
according to a multivariate Cox model
Variables
Hazard
ratio
95%
confidence
intervals P-value
Variables not in the model
Alkaline phosphatase 1.11 0.84–1.48 0.45
Performance status 1.22 0.70–2.12 0.47
Variables in the model
Number of metastatic sites 1.16 1.07–1.25 0.000
Pain score 1.13 1.06–1.20 0.000
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shormone-refractory phase, although only 7 months on average,
was distributed over a wide range (1–39 months). In all, 90% of
patients died, 58.8% of which died of disease without experiencing
an SRE. Among those still alive at the last follow-up appointment,
five were still SREs-free more than 4 years since the date of
hormone refractoriness.
The first comment to this study is that many patients are
expected to develop SREs in the hormone-refractory phase of the
disease, but they constitute a minority of those potentially at risk.
In this respect, the hormone-refractory patients were a hetero-
geneous population, since SREs occurred within a few months in
many patients or sometimes even years later in others.
Knowing whether the chance to develop SREs is high or low and
whether an SRE may occur within months or years is useful for
physicians when planning the frequency of follow-up investiga-
tions and guiding decisions about the choice of treatment. In
addition, the identification of predictive factors for developing
SREs may be a valuable aid in designing studies to test bone
resorption inhibitors that can prevent adverse skeletal events,
since an imbalance in these factors when comparing study arms
could lead to biased results.
Zoledronic acid administration in hormone-refractory prostate
cancer patients with metastatic bone disease has been demon-
strated to significantly reduce the frequency of SREs. No patients
in our series received zoledronic acid, but 31 had been treated with
a single dose of pamidronate, another bisphosphonate (Berruti
et al, 2002). Since pamidronate had failed to reduce SREs in the
prostate cancer population (Lipton et al, 2002), these patients were
not removed from the analysis.
A recent study pointed out that zoledronic acid administration
in bone metastatic prostate cancer patients with hormone-
refractory disease is not cost-effective since the costs of adminis-
tering the drug outweigh the savings on the cost of medical care
linked to the reduction in SREs (Reed et al, 2004). We believe,
however, that the use of this drug might be more convenient if it
were administered only to patients at risk of developing SREs.
Among the skeletal related parameters considered in the present
study as predictive factors for SREs, disease estent in bone, bone
pain, serum ALP and urinary NTx displayed a significant
association in univariate analysis, while serum calcium and type
of bone lesions did not. In a previous paper, we reported that
urinary deoxypyridinoline, a bone resorption marker, showed a
significant correlation with the probability to develop SREs
(Berruti et al, 2000). In the present study, NTx also showed a
similar relationship. N-telopeptide of type one collagen has
recently been demonstrated to be an independent predictor of
SREs in prostate cancer patients and those with non-small-cell
lung cancer or other solid tumours (Brown et al, 2005). Our data
are in line with these results. Unfortunately, this marker failed to
be an independent predictor when adjusted for DE in bone. The
relationship between NTx with DE in bone could provide a
possible explanation for this failure. N-telopeptide of type one
collagen, however, was available in about 50% of cases, so that
caution should be taken when interpreting data coming from a
subgroup analysis. Serum calcium is notoriously tightly regulated
and so does not reflect the bone matrix break-down. This is
probably the reason why it failed to show a predictive role in our
series. The absence of a relationship between the type of bone
lesions and the occurrence of SREs is somewhat surprising. It
should be noted, however, that the small number of patients with
lytic/mixed bone lesions may have limited the power of the
analysis.
The multivariate analysis identified bone pain and DE in bone as
two independent parameters predictive for the occurrence of SREs.
By combining these two variables, dichotomised at median value,
we defined three patient subgroups. The group with low pain score
and limited DE in bone had a low incidence of SREs, whereas the
group with high pain score and extensive tumour load in bone had
a high incidence of SREs. The incidence of SREs in the patients
group with either of these two predictors was intermediate. The
time-to-first-SRE curves show that patients with heavy tumour
load in bone and high pain score developed SREs much earlier
than those with less tumour load and bone pain. This observation
comes somewhat expectedly but has never been reported before.
Disease extent in bone was found to be predictive for spinal cord
compression in a small study on 68 cases, 61 of which had
hormone-refractory disease (Bayley et al, 2001), thus confirming
our observations. In the same study, however, the authors reported
a direct relationship between the occurrence of spinal cord
compression and the duration of androgen deprivation therapy,
a finding that contrasts with our results.
Recognised prognostic factors such as Gleason score at
diagnosis, Hb, LDH, PS and albumin (Smaletz et al, 2002; Halabi
et al, 2003) were confirmed as being significantly related with
poor survival but failed to be predictive for SREs; in addition,
some factors predictive for SREs were also negative prognostic
parameters. By combining prognostic parameters (Smaletz et al,
2002; Halabi et al, 2003) with predictive factors of SREs, it may be
possible to identify a patient subset with a higher likelihood of
dying before the onset of SREs in which bisphosphonate therapy
could be potentially avoided.
In our series, the duration of androgen deprivation therapy
significantly correlated with the occurrence of SREs in the
hormone-sensitive phase of the disease, thus confirming its
causative role (Daniell et al, 2000; Oefelein et al, 2002), but failed
to show a predictive role when the disease become hormone
refractory. In this study, benign SREs cannot be distinguished
from malignant SREs, which may be an obstacle to assessing the
real impact of iatrogenic SREs. This issues needs to be addressed in
future studies. Noteworthy, however, is that the majority of SREs
were distributed among patients with heavy tumour load in bone.
These data suggest that in the hormone-refractory phase of the
disease bone loss due to tumour-induced osteolysis prevail over an
iatrogenic effect.
In a large series of men with prostate carcinoma prospectively
followed after initiation androgen deprivation therapy until death,
the duration of hormone therapy conferred an independent risk
for SREs (Krupski et al, 2004). In this study, however, only skeletal
fractures were considered as SREs, and no distinction was made
between SREs occurring before or after the onset of hormone
refractory disease.
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Figure 1 Time to the onset of SRE in patients with low pain and limited
disease extent in bone (Pain /DE )( ) vs patients with great bone
pain and heavy tumour load in bone (Painþ/DEþ)( ), vs patients
with either of these two predictors ( ).
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sIn conclusion, prostate cancer patients with hormone-refractory
disease are generally more likely to die of the disease than to
develop SREs. Our study shows that bone pain intensity and DE in
bone, two variables easily available in clinical routine, indepen-
dently predict the occurrence of SREs in this patient population.
By combining these parameters we found patient subsets with a
different risk of SREs. These findings have several implications: (1)
they could help physicians in planning the most appropriate skel-
etal follow-up for individual patients; (2) they suggest future trials
aimed at delaying zoledronic acid administration in patients with
low risk of developing SREs and/or avoiding drug delivery in
patients with a high probability of dying of disease before the
occurrence of SREs (ie patients with very limited disease in bone
and concomitant visceral metastases). Finally, our results may prove
useful for stratifying patients enrolled in clinical trials for testing the
efficacy of new bone resorption inhibitors to prevent SREs.
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